Big pharma also facing scientific fraudMonday’s Le Monde (Eco & Enterprises supplement, p1) published an article saying that big pharma like Pfizer, AstraZeneca and Novartis have to deal with scientific fraud.
Opiates crisis shakes AmericaTuesday’s Le Monde (Economy and Enterprises supplement, p8) published an article about the scandal around U.S. pharma company Insys, which is accused of corrupting doctors in order to push sales of its opiate-based painkillers.
Amazon prepares entry to U.S. prescription medicines wholesale marketOn Thursday, Le Monde (Economy and Enterprises supplement, p5) reported that giant U.S. online retailer Amazon may be about to enter the prescription medicines retail business.
Sanofi signs deal to use A.I. in R&D on vaccinesTuesday’s Le Figaro (brief p21) reported briefly on the deal inked by Sanofi and U.S. biotech Berg that will allow the big pharma to rely on the biotech’s artificial intelligence platform to increase the performance of its R&D efforts in vaccines.
French government to launch HPV self-test campaignFree newspaper 20 Minutes reported on Monday (p14) that French public cancer institute INCa will launch a large-scale HPV diagnosis campaign which will for the first time include the use of self-testing.
Eurocept acquires biotech Lucane PharmaParisian biotech Lucane Pharma has been bought by Dutch pharma Eurocept from investment firm Seventure Partners, Capital Finance (website) reported on Tuesday.
Advicenne prepares IPOFrench biotech Advicenne has submitted an official request to French market authorities in view of an IPO on Euronext.
Chines firm buys wholesaler TridemTuesday’s Les Echos (website) reported that French pharmaceutical wholesaler Tridem has been bought by Chinese conglomerate Fosun for up to 63 million euros.
National Assembly votes extension of mandatory vaccinesMonday’s Le Monde (brief p9) and La Croix (p9) noted that the French National Assembly (lower house of parliament) has approved a measure extending the number of mandatory vaccines to 11, for children born as of early 2018.
Op2Lysis seeks capital increaseYoung French company Op2Lysis is seeking to raise 250,000 euros to advance the development of its stroke treatment, reported Le Parisien (Economy supplement, brief p6) on Monday.
New target for malariaMonday’s Le Figaro (p9) reported on the discovery by Swiss researchers of a potential new target in the treatment of malaria.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.